Eli Lilly's Obesity Pipeline Is Getting Crowded. That's Great News for Investors

Resumen detallado
Eli Lilly's pipeline could help it survive a slew of brand-new launches in the weight loss drug market.
The weight loss drug market is one of the hottest areas in the pharmaceutical industry right now, and according to projections, it will continue growing rapidly over the medium term. Eli Lilly (LLY -0.30%) is currently a leader in this space.
Its financial results in recent quarters have been excellent, partly thanks to its obesity franchise. Even though some investors worry that increased competition will erode Eli Lilly's market share, the company's pipeline appears strong enough to withstand the challenge. Here's more on why Eli Lilly is well positioned to remain the top player in the anti-obesity space over the next five years.
Eli Lilly's approved weight loss portfolio currently includes injectable tirzepatide, sold under the brand name Zepbound in this market, and Foundayo, an oral anti-obesity treatment. Zepbound was first approved about three years ago, and it is posting outstanding sales growth. In the third quarter, Zepbound's revenue increased by 49% year over year to $5.4 billion.
Foundayo earned approval in April, and it has had a fairly strong commercial ramp-up so far. In the third quarter, it generated $184 million in revenue. Competitors might launch treatments that rival -- or perhaps even exceed -- Zepbound and Foundayo in efficacy. But Eli Lilly will do the same, which may help the company defend, or even improve, its market share. Below are some of Eli Lilly's most important pipeline candidates.
Note that two of these candidates, retatrutide and EloraTZP, achieved greater weight loss than Zepbound, although head-to-head comparisons remain somewhat limited. This does raise a potential problem, however.
Will these new medicines cannibalize Zepbound sales? Some of that will happen, and for what it's worth, it's better if Eli Lilly's own products capture sales from older ones rather than other pharmaceutical giants taking market share away from the company. However, newer products will also help Eli Lilly expand the market.
First, medicines with greater…
I…
Inicio del artículo, extracto de The Motley Fool. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)




